TRAXFirst Tracks Biotherapeutics, Inc.

Healthcare
$16.37

The financials

First Tracks Biotherapeutics, Inc. by the numbers

The next results filing is expected around Nov 11, 2026, a quarter after the last one.

First Tracks Biotherapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q1 2025Change
Operating income−$35M−$51Mn/a
Net income−$33M−$47Mn/a
Diluted EPS−$0.95−$1.55n/a

Biotechnology

The closest names by size in the same industry

Compare peers
JANX+3.4%
Janux Therapeutics, Inc.
WVE-1.8%
Wave Life Sciences Ltd.
CGEM-0.96%
Cullinan Therapeutics, Inc.
CRVS-1.9%
Corvus Pharmaceuticals, Inc.
XNCR+0.99%
Xencor, Inc.
EYPT+4.2%
EyePoint, Inc.